Please login to the form below
Stivarga
This page shows the latest Stivarga news and features for those working in and with pharma, biotech and healthcare.
FDA clears Blueprint’s $32k-per-month GI cancer drug
imatinib) and Pfizer’s Sutent (sunitinib), which are also available as generics, and Bayer’s Stivarga (regorafenib) which is still in patent. ... The FDA’s decision has been delayed by three months as Blueprint awaits data from a head-to-head trial
Latest news
-
Chi-Med goes for third IPO in Hong Kong
It was the second VEGF inhibitor to reach the Chinese market, after Bayer’s Stivarga, and Chi-Med is partnering with Eli Lilly to commercialise the drug across China whilst also
-
Chi-Med and Lilly’s cancer drug Elunate a milestone for China
where there is just one other VEGF drug currently available, Bayer’s Stivarga.
-
Home-grown colorectal cancer drug approved in China
Elunate will have to go up against well-established oral drugs like Bayer’s multikinase inhibitor Stivarga (regorafenib) and Taiho Oncology’s Lonsurf (trifluridine/tipiracil) in the third-line setting.
-
Another IO knockback as Tecentriq combo fails phase III trial
cancer (CRC) showed no benefit on overall survival compared to Bayer’s Stivarga (regorafenib), a drug typically used in that hard-to-treat population.
-
Pharma sales help Bayer escape the worst from a bumpy 2017
The two brands, along with cancer drugs Xofigo and Stivarga and pulmonary hypertension treatment Adempas, are seen by the company as its key growth brands.
More from news
Approximately 12 fully matching, plus 25 partially matching documents found.
Latest Intelligence
-
Deal Watch table for August 2013
Onyx Pharmaceuticals / Amgen. Acquisition. Cancer drugs including Kyprolis, Nexavar and Stivarga.
-
Pharma deals during August 2013
To add to the glitter are two marketed drugs partnered with Bayer: Nexavar (sorafenib) for the treatment of advanced kidney and liver cancer and Stivarga (regorafenib) for the treatment of metastatic
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
Bayer’s former oncology head Robert Rosen joins AP Pharma
Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Biogen and Happify Health team up to create digital platform for MS patients
- Moderna to launch Innovation and Technology Center in the UK
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- Live Webinar: Navigating the Nuances of Europe's MedTech Industry
- Why project managers are key to creating quality content
- Pfizer and BioNTech sign $3.2bn COVID-19 vaccine supply agreement with US government
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis
- ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
- A creative awakening – how pharma is bringing innovation to the patient journey
- AstraZeneca’s Evusheld phase 3 results show high level of protection against COVID-19
- Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
- EMA grants Bavarian Nordic access to PRIME scheme for RSV vaccine candidate
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
PMHub
McCann Health Medical Communications
We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
